These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29805145)

  • 1. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.
    Turner L
    Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.
    Sipp D
    Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct-to-consumer marketing of stem cell interventions by Canadian businesses.
    Turner L
    Regen Med; 2018 Sep; 13(6):643-658. PubMed ID: 30255734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA's claims over stem cells upheld.
    Cyranoski D
    Nature; 2012 Aug; 488(7409):14. PubMed ID: 22859178
    [No Abstract]   [Full Text] [Related]  

  • 5. US businesses engaged in direct-to-consumer marketing of perinatal stem cell interventions following the Food and Drug Administration's enforcement discretion era.
    Turner L; Wang JC; Martinez JR; Najjar S; Rajapaksha Arachchilage T; Sahrai V
    Cytotherapy; 2024 Apr; 26(4):393-403. PubMed ID: 38340106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US clinics marketing unproven and unlicensed adipose-derived autologous stem cell interventions.
    Turner LG
    Regen Med; 2015 May; 10(4):397-402. PubMed ID: 26022761
    [No Abstract]   [Full Text] [Related]  

  • 7. The direct-to-consumer market for stem cell-based interventions in Australia: exploring the experiences of patients.
    Waldby C; Hendl T; Kerridge I; Lipworth W; Lysaght T; Munsie M; Stewart C
    Regen Med; 2020 Jan; 15(1):1238-1249. PubMed ID: 32009513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selling stem cell 'treatments' as research: prospective customer perspectives from crowdfunding campaigns.
    Snyder J; Turner L
    Regen Med; 2018 Jun; 13(4):375-384. PubMed ID: 29985757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis.
    Knoepfler PS; Turner LG
    Regen Med; 2018 Jan; 13(1):19-27. PubMed ID: 29327974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rejuvenating Regenerative Medicine Regulation.
    Charo RA; Sipp D
    N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
    [No Abstract]   [Full Text] [Related]  

  • 11. The Need for Beneficence and Prudence in Clinical Innovation with Autologous Stem Cells.
    Lipworth W; Stewart C; Kerridge I
    Perspect Biol Med; 2018; 61(1):90-105. PubMed ID: 29805150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global bionetworks and challenges in regulating autologous adult stem cells.
    Lysaght T; Kerridge I; Sipp D; Porter G; Capps BJ
    Am J Med; 2013 Nov; 126(11):941-3. PubMed ID: 24157285
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulatory claims made by US businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies.
    Turner L; Martinez JR; Najjar S; Arachchilage TR; Sahrai V; Wang JC
    Regen Med; 2023 Nov; 18(11):857-868. PubMed ID: 37867326
    [No Abstract]   [Full Text] [Related]  

  • 14. US stem cell clinics, patient safety, and the FDA.
    Turner L
    Trends Mol Med; 2015 May; 21(5):271-3. PubMed ID: 25945404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem cell clinics: risk of proliferation.
    Sissung TM; Figg WD
    Lancet Oncol; 2020 Feb; 21(2):205-206. PubMed ID: 32007195
    [No Abstract]   [Full Text] [Related]  

  • 16. Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action.
    Caulfield T; Murdoch B
    BMC Med Ethics; 2019 Aug; 20(1):51. PubMed ID: 31383026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
    Turner L; Knoepfler P
    Cell Stem Cell; 2016 Aug; 19(2):154-157. PubMed ID: 27374789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulating the advertising and promotion of stem cell therapies.
    von Tigerstrom B
    Regen Med; 2017 Oct; 12(7):815-826. PubMed ID: 29112482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vulnerabilities and the Use of Autologous Stem Cells for Medical Conditions in Australia.
    Hendl T
    Perspect Biol Med; 2018; 61(1):76-89. PubMed ID: 29805149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy claims made by US businesses marketing purported stem cell treatments and exosome therapies.
    Turner L; Martinez JR; Najjar S; Arachchilage TR; Sahrai V; Wang JC
    Regen Med; 2023 Oct; 18(10):781-793. PubMed ID: 37795701
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.